BIO-Europe 2026: Abalos Therapeutics will have p1 data on its lead project in 1H27, a non-oncolytic arenavirus-based product that is being tested in refractory/relapsed solid tumors
CEO Gerben Moolhuizen tells us how the company has developed an arena-virus based platform that allows for systemic delivery, and a more targeted approach than other virus-based immunotherapies.
Coverage brought to you by










.png)
